Audentes Therapeutics (BOLD) PT Set at $44.00 by BMO Capital Markets
Audentes Therapeutics (NASDAQ:BOLD) received a $44.00 target price from investment analysts at BMO Capital Markets in a report issued on Friday. The firm presently has a “buy” rating on the biotechnology company’s stock. BMO Capital Markets’ price objective would suggest a potential upside of 7.82% from the company’s previous close.
A number of other equities research analysts have also recently issued reports on the company. Zacks Investment Research cut Audentes Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, November 17th. BidaskClub cut Audentes Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 6th. Bank of America restated a “buy” rating and set a $33.00 price objective (up previously from $23.00) on shares of Audentes Therapeutics in a report on Friday, September 22nd. Leerink Swann restated an “outperform” rating and set a $29.00 price objective (up previously from $22.00) on shares of Audentes Therapeutics in a report on Wednesday, November 15th. Finally, Raymond James Financial initiated coverage on Audentes Therapeutics in a report on Thursday, October 12th. They set a “market perform” rating for the company. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $35.00.
Audentes Therapeutics (NASDAQ BOLD) opened at $40.81 on Friday. Audentes Therapeutics has a 1-year low of $13.90 and a 1-year high of $41.80. The company has a market capitalization of $1,220.00 and a PE ratio of -11.73.
In other news, Director Louis G. Lange sold 18,000 shares of Audentes Therapeutics stock in a transaction that occurred on Friday, December 22nd. The shares were sold at an average price of $30.88, for a total value of $555,840.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Suyash Prasad sold 8,000 shares of Audentes Therapeutics stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $28.53, for a total transaction of $228,240.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 36,000 shares of company stock valued at $1,052,480. 47.30% of the stock is owned by company insiders.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in BOLD. Redmile Group LLC raised its position in shares of Audentes Therapeutics by 77.8% in the second quarter. Redmile Group LLC now owns 1,459,616 shares of the biotechnology company’s stock valued at $27,922,000 after buying an additional 638,780 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Audentes Therapeutics by 130.3% in the second quarter. Vanguard Group Inc. now owns 678,412 shares of the biotechnology company’s stock valued at $12,978,000 after buying an additional 383,837 shares in the last quarter. Artal Group S.A. acquired a new stake in shares of Audentes Therapeutics in the third quarter valued at approximately $5,602,000. State Street Corp raised its position in Audentes Therapeutics by 231.6% during the second quarter. State Street Corp now owns 221,276 shares of the biotechnology company’s stock valued at $4,234,000 after purchasing an additional 154,544 shares in the last quarter. Finally, Alliancebernstein L.P. raised its position in Audentes Therapeutics by 31.5% during the second quarter. Alliancebernstein L.P. now owns 640,654 shares of the biotechnology company’s stock valued at $12,256,000 after purchasing an additional 153,617 shares in the last quarter. Institutional investors own 78.95% of the company’s stock.
About Audentes Therapeutics
Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).
Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.